Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD1 | P17405 | 1/20 | 0.45 |
| ▸ | ITPR3 | Q14573 | 5/20 | 0.44 |
| ▸ | ITPR2 | Q14571 | 2/20 | 0.44 |
| ▸ | ITPR1 | Q14643 | 2/20 | 0.44 |
| ▸ | INPP5A | Q14642 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5381912 | 0.82 | SMPD1 (0.48) | SMPD1ITPR3ITPR2ITPR1 | |
| SCHEMBL7796118 | 0.82 | SMPD1 (0.48) | SMPD1ITPR3ITPR2ITPR1 | |
| SCHEMBL4595256 | 0.82 | SMPD1 (0.48) | SMPD1ITPR3ITPR2ITPR1 | |
| SCHEMBL5378658 | 0.82 | SMPD1 (0.48) | SMPD1ITPR3ITPR2ITPR1 | |
| SCHEMBL4596697 | 0.82 | SMPD1 (0.48) | SMPD1ITPR3ITPR2ITPR1 | |
| SCHEMBL30237668 | 0.82 | SMPD1 (0.54) | SMPD1ITPR3ITPR2ITPR1INPP5A | |
| SCHEMBL4143599 | 0.81 | SMPD1 (0.47) | SMPD1ITPR3ITPR2ITPR1 | |
| SCHEMBL2045173 | 0.79 | SMPD1 (0.45) | SMPD1ITPR3ITPR2ITPR1 | |
| SCHEMBL28394922 | 0.79 | SMPD1 (0.45) | SMPD1ITPR3ITPR2ITPR1INPP5A | |
| SCHEMBL2819346 | 0.79 | SMPD1 (0.41) | SMPD1ITPR3ITPR2ITPR1INPP5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 51 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116745410-A | Genetically engineered bacteria capable of producing cytokinins with isoprenoid side chains | 阿西耶斯生物公司 | 2023-09-12 | — | — | CN | claimed |
| CN-109536427-B | Lactobacillus engineering bacterium with improved acid stress resistance | 江南大学 | 2020-11-06 | — | — | CN | claimed |
| CN-118147029-A | Engineered immunostimulatory bacterial strains and uses thereof | 阿克蒂姆治疗有限公司 | 2024-06-07 | — | — | CN | disclosed |
| US-20240124907-A1 | Engineered Biosynthetic Pathways for Production of Histamine by Fermentation | ZYMERGEN INC. (US) | 2024-04-18 | — | — | US | disclosed |
| CN-112673092-B | Engineered immunostimulatory bacterial strains and uses thereof | 阿克蒂姆治疗有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-11887698-B2 | Method and electronic device for building comprehensive genome scale metabolic model | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2024-01-30 | — | — | US | disclosed |
| CN-116916944-A | Vaccine, therapeutic agent and RNA delivery platform based on immunostimulatory bacteria | 阿克蒂姆治疗有限公司 | 2023-10-20 | — | — | CN | disclosed |
| CN-116745410-A | Genetically engineered bacteria capable of producing cytokinins with isoprenoid side chains | 阿西耶斯生物公司 | 2023-09-12 | — | — | CN | disclosed |
| US-11739355-B2 | Engineered biosynthetic pathways for production of histamine by fermentation | ZYMERGEN INC. (US) | 2023-08-29 | — | — | US | disclosed |
| CN-116529258-A | Interleukin-2-Fc fusion proteins and methods of use | 吉利德科学公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-116249779-A | Immunostimulatory bacteria delivery platform and use thereof for delivering therapeutic products | 阿克蒂姆治疗有限公司 | 2023-06-09 | — | — | CN | disclosed |
| US-20080050774-A1 | Computer-based system for monitoring differential expression; host cells | NOVOZYMES A/S (DK) | 2008-02-28 | — | — | US | disclosed |
| US-20060275905-A1 | Gram positive bacterial mutants and methods of generating and using such mutants | THE UNIVERSITY OF CHICAGO | 2006-12-07 | — | — | US | disclosed |
| EP-1066309-A4 | LIBRARIES OF EXPRESSIBLE GENE SEQUENCES | INVITROGEN CORP (US) | 2005-10-19 | — | — | EP | disclosed |
| US-20050085436-A1 | Method to treat conditions associated with insulin signalling dysregulation | LI HAO (US) | 2005-04-21 | — | — | US | disclosed |
| US-6632636-B1 | Use of vectors, host cells and methods for producing Moraxella catarrhalis proteins, or portions thereof, for identification of diagnostic and therapeutic compositions | ELITRA PHARMACEUTICALS INC. | 2003-10-14 | — | — | US | disclosed |
| US-6583266-B1 | Peptide for use in the diagnosis and treatment of skin disorders and tuberculosis | GENOME THERAPEUTICS CORPORATION | 2003-06-24 | — | — | US | disclosed |
| JP-2002209574-A | GENE-BROKEN YEAST | KANEGAFUCHI CHEM IND CO LTD | 2002-07-30 | — | — | JP | disclosed |
| EP-1066309-A1 | LIBRARIES OF EXPRESSIBLE GENE SEQUENCES | INVITROGEN CORPORATION (US) | 2001-01-10 | — | — | EP | disclosed |
| WO-1999051620-A1 | LIBRARIES OF EXPRESSIBLE GENE SEQUENCES | INVITROGEN CORPORATION (US) | 1999-10-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050085436-A1 | Method to treat conditions associated with insulin signalling dysregulation | IAPP, HASPIN, IRS1 | SMPD1 203/4885ITPR3 1190/4885ITPR2 1222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.